Circulating Tumor HPV DNA in Patients With Stage I and II HPV-Associated Head and Neck Cancer After Surgery

Saskia Naegele; Dipon Das; Shun Hirayama; Sophia Z Shalhout; Hang Lee; Jeremy D Richmon; Daniel L Faden

doi:10.1001/jamaoto.2024.0740

Circulating Tumor HPV DNA in Patients With Stage I and II HPV-Associated Head and Neck Cancer After Surgery

JAMA Otolaryngol Head Neck Surg. 2024 Apr 25:e240740. doi: 10.1001/jamaoto.2024.0740. Online ahead of print.

Authors

Saskia Naegele^{1

2}, Dipon Das^{1

2}, Shun Hirayama^{1

2}, Sophia Z Shalhout^{1

2

3}, Hang Lee⁴, Jeremy D Richmon^{1

2}, Daniel L Faden^{1

2

5}

Affiliations

¹ Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts.
² Massachusetts Eye and Ear, Boston.
³ Department of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital, Boston.
⁴ Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston.
⁵ Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

PMID: 38662357
PMCID: PMC11046405 (available on 2025-04-25)
DOI: 10.1001/jamaoto.2024.0740

No abstract available

Plain language summary

This cohort study examines the association of posttreatment circulating tumor human papillomavirus DNA (ctHPVDNA) with residual disease and 2-year overall survival and recurrence-free survival in patients with HPV-associated head and neck cancer.